U.S. Capital Wealth Advisors LLC Buys 7,756 Shares of Johnson & Johnson (NYSE:JNJ)

U.S. Capital Wealth Advisors LLC grew its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 6.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 122,958 shares of the company's stock after buying an additional 7,756 shares during the quarter. U.S. Capital Wealth Advisors LLC's holdings in Johnson & Johnson were worth $20,391,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Brass Tax Wealth Management Inc. raised its holdings in Johnson & Johnson by 5.6% in the 1st quarter. Brass Tax Wealth Management Inc. now owns 4,343 shares of the company's stock worth $720,000 after purchasing an additional 230 shares during the period. Financial Counselors Inc. raised its holdings in Johnson & Johnson by 8.3% in the 1st quarter. Financial Counselors Inc. now owns 182,888 shares of the company's stock worth $30,330,000 after purchasing an additional 13,957 shares during the period. YANKCOM Partnership raised its holdings in Johnson & Johnson by 9.5% in the 1st quarter. YANKCOM Partnership now owns 6,984 shares of the company's stock worth $1,158,000 after purchasing an additional 605 shares during the period. Callan Capital LLC raised its holdings in Johnson & Johnson by 30.5% in the 1st quarter. Callan Capital LLC now owns 9,090 shares of the company's stock worth $1,507,000 after purchasing an additional 2,122 shares during the period. Finally, TD Private Client Wealth LLC increased its stake in Johnson & Johnson by 9.8% in the 1st quarter. TD Private Client Wealth LLC now owns 61,908 shares of the company's stock worth $10,267,000 after buying an additional 5,501 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Trading Down 0.5%

NYSE JNJ traded down $0.82 during trading on Friday, hitting $156.87. The stock had a trading volume of 7,866,488 shares, compared to its average volume of 8,066,975. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. The stock has a market capitalization of $377.44 billion, a price-to-earnings ratio of 17.45, a P/E/G ratio of 2.15 and a beta of 0.41. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The stock has a 50 day simple moving average of $153.75 and a 200 day simple moving average of $154.43.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. Sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 3.31%. The ex-dividend date was Tuesday, May 27th. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's payout ratio is currently 57.84%.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of analyst reports. Morgan Stanley reiterated an "underperform" rating on shares of Johnson & Johnson in a research note on Thursday. Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Leerink Partnrs lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. The Goldman Sachs Group upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their price target for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Finally, Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Eleven research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and an average price target of $171.00.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.